title: Analysis of the ligand binding site of the 5-HT3 receptor using site directed mutagenesis: importance of glutamate 106.
abstract: The 5-HT3 receptor is a ligand-gated ion channel with significant structural similarity to the nicotinic acetylcholine receptor. Several regions that form the ligand binding site in the nicotinic acetylcholine receptor are partially conserved in the 5-HT3 receptor, presumably reflecting the conserved signal transduction mechanism. Specific amino acid differences in these regions may account for their distinct ligand recognition properties. Using site-directed mutagenesis, we have replaced one of these residues, glutamate 106 (E106), with aspartate (D), asparagine (N), alanine (A) or glutamine (Q) and characterized the ligand-binding and electrophysiological properties of the mutant receptors after transient expression in HEK-293 cells. The affinity for the selective 5-HT3 receptor antagonist [3H]GR65630 was decreased 14-fold in the mutant E106D (Kd = 3.69 +/- 0.32 nM) when compared to wildtype (WT, E106) 5-HT3 receptor (0.27 +/- 0.03 nM), while the affinity for E106N was unchanged (0.42 +/- 0.07 nM, means +/- SEM, n = 3-10). Decreased affinities for both E106D and E106N were observed for the antagonists granisetron, ondansetron and renzapride and for the agonists 5-HT (130- and 30-fold) and 2-methyl-5-HT (250- and 20-fold), respectively. Both mutants still formed 5-HT-activatable ion channels, but the high Hill coefficient of the concentration effect curves in wildtype (2.0) was decreased to unity in both cases. The EC50 of 5-HT was increased seven-fold in E106N (8.7 microM) when compared to wildtype (1.2 microM), but unchanged in E106D, and the potency of the antagonist ondansetron for both mutants was decreased. E106A and E106Q expressed poorly preventing a detailed characterization. These data suggest that E106 contributes to the ligand-binding site of the 5-HT3 receptor and may form an ionic or hydrogen bond interaction with the primary ammonium group of 5-HT.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, University of Alberta, Edmonton, Canada.
authors.forename: F G
authors.initials: FG
authors.lastname: Boess
authors.forename: L J
authors.initials: LJ
authors.lastname: Steward
authors.forename: J A
authors.initials: JA
authors.lastname: Steele
authors.forename: D
authors.initials: D
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Reid
authors.forename: T A
authors.initials: TA
authors.lastname: Glencorse
authors.forename: I L
authors.initials: IL
authors.lastname: Martin
mesh_terms: D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D002460:Cell Line; D018076:DNA, Complementary / Q000096:biosynthesis; D004594:Electrophysiology; D018698:Glutamic Acid / Q000502:physiology*; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008024:Ligands; D051379:Mice; D016297:Mutagenesis, Site-Directed / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D011869:Radioligand Assay; D011985:Receptors, Serotonin / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism
chemical_list: D018076:DNA, Complementary; D008024:Ligands; D011985:Receptors, Serotonin; D012701:Serotonin; D018698:Glutamic Acid